linjc16/ctgov huggingface dataset:
Swiss Transplant Cohort Study

Study Overview
=================
Brief Summary
-----------------
The Swiss Transplant Cohort Study is an observational prospective cohort study enrolling all patients after solid organ and stem cell transplantation since 5/2008 in Switzerland. Predefined variables are collected at defined time points. Individual samples (PBMC, plasma, DNA) will be stored for future projects. Data relevant to transplantation outcome with emphasis on immunological and infectious complications as well as psychosocial variables will be gathered.

Official Title
-----------------
Swiss Transplant Cohort Study

Conditions
-----------------
All Transplanted Individuals in Switzerland

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: All patients after organ and stem cell (planned 2009) transplantation. Exclusion criteria: No informed consent given

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Outcome after transplantation | Various endpoints | open |
Comparison of Various Supraglottic Airway Devices for Fiberoptical Guided Tracheal Intubation

Study Overview
=================
Brief Summary
-----------------
Placement of a supraglottic airway device Fiberoptical verification of pharyngeal position

Detailed Description
-----------------
Feasibility for fiberoptical verification of pharyngeal position of supraglottic airway device

Official Title
-----------------
Comparison of Various Supraglottic Airway Devices for Fiberoptical Guided Tracheal Intubation

Conditions
-----------------
Intubation; Difficult

Intervention / Treatment
-----------------
* Device: SAD 1
* Device: SAD 2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: will to participate Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SAD 1<br>FOI for placement | Device: SAD 1<br>* Placement and fiberoptic control<br>|
| Experimental: SAD 2<br>FOI für placement | Device: SAD 2<br>* Placement and fiberoptic control<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visibility of vocal cords |  | intraoperative |
Functional MRC With Eovist for Acute Cholecystitis

Study Overview
=================
Brief Summary
-----------------
Functional magnetic resonance cholangiography (fMRC) with gadoxetate disodium (Eovist) is an accurate method of diagnosing acute cholecystitis.

Detailed Description
-----------------
Primary Objective: To determine the accuracy of fMRC in evaluating patients with suspected cholecystitis. Secondary Objective: To compare the results of fMRC with conventional hepatobiliary scintigraphy.

Official Title
-----------------
Accuracy of Functional MRC With Gadoxetate Disodium in the Diagnosis of Acute Cholecystitis: Comparison With Hepatobiliary Scintigraphy

Conditions
-----------------
Acute Cholecystitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Symptoms of right upper quadrant pain with ambiguous US (and/or CT) findings Standard of care nuclear medicine hepatobiliary scan to rule out acute cholecystitis - Exclusion Criteria: Scheduled for emergent surgery, or is otherwise determined by the Investigator that the subject is clinically unsuitable for the study Glomerular filtration rate (GFR) below 60 mL/min/1.73m2 Total bilirubin above 3.0 mg/dL Inability to provide informed consent (altered or diminished mental status) Allergic to morphine Known or suspected hypersensitivity to gadolinium-based agents The standard MRI contraindications apply, including but not limited to: having a pacemaker or other implanted electronic device, metal foreign bodies within the eye, aneurysm clips, heart valve prosthesis, vascular stents, coils, intrauterine devices (IUDs), penile implants, inferior vena cava (IVC) filters, gunshot wounds with retained bullet fragments. Pregnant or breast-feeding -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| acute cholecystitis<br>acute cholecystitis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of positive cases of acute cholecystitis | The primary outcome measure is the number of positive cases of acute cholecystitis on functional magnetic resonance imaging | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute cholecystitis
Epidemiological Characteristics and Prevention Methods of Blisters in Ultra-trail Runners

Study Overview
=================
Brief Summary
-----------------
PRIMARY OBJECTIVE : To evaluate the methods of prevention of the appearance of blisters set up by the runners before and during an ultra-trail SECONDARY OBJECTIVES : To evaluate : The main locations of blisters. The severity of blisters The effectiveness of prevention methods To evaluate the incidence of blisters in an ultra-trail context.

Detailed Description
-----------------
MAIN JUDGEMENT CRITERIA : Prevention methods used before an ultra-trail via a self-questionnaire SECONDARY JUDGING CRITERIA : Location of blisters, via a self-questionnaire Presence or not of blisters at the end of the ultra-trail or at the time of abandonment STUDY SCHEME : Post-race questioning

Official Title
-----------------
Caractéristiques épidémiologiques et méthodes de prévention Des Ampoules Chez Les Coureurs d'Ultra-trail

Conditions
-----------------
Sport Injury, Blister of Foot

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ultra-trail participants with validated registration Exclusion Criteria: Presence of blisters or other skin lesions on the feet before the race

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevention methods used before an ultra-trail via a self-questionnaire | Prevention methods used before an ultra-trail | Through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Location of blisters, via a self-questionnaire | Location of blisters on the feet | Through study completion, an average of 1 year | 
| Presence or not of blisters at the end of the ultra-trail or at the time of abandonment | Presence or not of blisters at the end | Through study completion, an average of 1 year |
Prospective Evaluation of the Clinical Utility of Endoscopically Placed Self-expandable Stents

Study Overview
=================
Brief Summary
-----------------
The investigators' believe that it is important to medical practice to obtain information on how expandable metal stents work in a large group of patients who have metal stents placed in the gastrointestinal system. The purpose of this research study is to collect information on the stent placement in our facility and how the patients responded to the stent placement.

Official Title
-----------------
Prospective Evaluation of the Clinical Utility of Endoscopically Placed Self-expandable Stents

Conditions
-----------------
Gastrointestinal Diseases

Intervention / Treatment
-----------------
* Procedure: Self-expandable stent placement via endoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older. Scheduled to undergo endoscopy with placement of self-expanding stent at the University of Florida, Gainesville, FL. Subject must be able to give informed consent. Exclusion Criteria: Any contraindication to performing endoscopy. Participation in another research protocol that could interfere or influence the outcomes measures of the present study. The subject is unable/unwilling to give informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients undergoing stent placement<br>Patients who are scheduled to undergo stent placement via endoscopy as part of their routine medical care. | Procedure: Self-expandable stent placement via endoscopy<br>* Self-expandable stent placement via endoscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The purpose of this research study is to collect information on the stent placement in our facility and how the patients responded to the stent placement. |  | at the time of stent placement | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Any Gastrointestinal problem that would require an endoscopically placed stent
Effects of L-Theanine in Boys With ADHD

Study Overview
=================
Brief Summary
-----------------
This study will examine the effects of L-theanine (an amino acid found in green tea) on the behavior, cognitive performance and sleep quality of boys with ADHD.

Official Title
-----------------
A Double Blind, Randomized Placebo Controlled Clinical Trial Examining the Effects of L-Theanine (Suntheanine®) in Male Child Subjects With Attention Deficit Hyperactivity Disorder

Conditions
-----------------
Attention Deficit Hyperactivity Disorder

Intervention / Treatment
-----------------
* Drug: L-theanine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of attention deficit hyperactivity disorder (ADHD) Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: L-theanine|This study will examine the effects of L-theanine (an amino acid found in green tea) on the behavior, cognitive performance and sleep quality of boys with ADHD.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive performance |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep quality, hyperactive behaviors, anxiety |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ADHD, attention, insomnia, hyperactivity, anxiety
Spot tm Tattooing of Biopsied Axillary Lymph Nodes With Ultrasound Guided in Breast Cancer Patients Prior to Surgery

Study Overview
=================
Brief Summary
-----------------
To assess feasibility and clinical utility of marking biopsied axillary lymph nodes with Spot at time of biopsy.

Detailed Description
-----------------
As part of the diagnostic tests for breast cancer sometimes necessary to perform a FNA or Core biopsy to a suspicious axillary lymph node. Presently there is no possibility to identify the examined gland at the surgery. If the gland was infected it's most important to remove it. The only technique that exists today is marking with a metal clip and the use of this technique is not profit, partly because of technical difficulties. In this trial the investigator will use a special ink which will be injected to the axillary lymph node during the biopsy and latter on the surgery the investigator will try to assess the ability to identify the marked gland.

Official Title
-----------------
Spot tm Tattooing of Biopsied Axillary Lymph Nodes With Ultrasound Guided in Breast Cancer Patients Prior to Surgery

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Procedure: SPOT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with findings suspicious of breast cancer (or known breast cancer) who undergo axillary lymph node biopsy Exclusion Criteria: Inability to sign Informed Consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Axillary lymph node FNA Biopsy<br>A carbon compound ink (SPOT) is injected to the axillary lymph node suspected to be infected with cancer | Procedure: SPOT<br>* Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intra operative identification the Spot TM marked node at the time of surgery |  | Within 1 year of enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between Spot TM marked lymph node and sentinel lymph node |  | Within 1 year of enrollment |
Efficacy of Ketoprofen Before Hysterosalpingography

Study Overview
=================
Brief Summary
-----------------
hysterosalpingography can cause pain and discomfort in several ways: Use of the tenaculum to grasp the cervix and straighten the uterus for proper insertion; trans-cervical actions including measuring uterine depth, inserting the cannula; and injection of the dye

Official Title
-----------------
Effect of Oral Ketoprofen on Hysterosalpingography Pain: A Randomized Controlled Trial

Conditions
-----------------
Pain Relief

Intervention / Treatment
-----------------
* Drug: Ketoprofen
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any patient came for Hysterosalpingography Exclusion Criteria: any patient has contraindication to Hysterosalpingography

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Ketoprofen<br>women will take one tablet 150 mg one hour before the procedure | Drug: Ketoprofen<br> <br> * Other names: bi profenid;|
| Placebo Comparator: Placebo<br>women will take one tablet placebo one hour before the procedure | Drug: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean pain score during the procedure |  | 5 minutes |
Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing

Study Overview
=================
Brief Summary
-----------------
The method to analyze the microsatellite instability (MSI) status by next-generation sequencing (NGS) has been established to assess the deficiency of DNA mismatch repair (MMR) system. The aim of our study is to evaluate the feasibility and reliability of this NGS method by testing the circulating tumor DNA (ctDNA) in blood sample of advanced colorectal cancer patients. If the result is positive, the MSI status could be easily learned without the acquisition of tissue samples.

Official Title
-----------------
Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing

Conditions
-----------------
Colorectal Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a biopsy proven histological diagnosis of colorectal carcinoma MSI status of tissue sample known by IHC or PCR method willing to participate and informed consent signed Exclusion Criteria: history of other malignant tumors patients with inflammatory bowel disease patients with familial adenomatous polyposis patients treated by surgery or adjuvant treatment pregnant or lactating women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MSI status in blood sample | ctDNA and leucocyte are extracted from blood sample for MSI detection by ColonCore NGS panel (Burning Rock, Guangzhou, China). There are three types of MSI status, MSI-H, MSI-L and MSS. | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Microsatellite Instability, Circulating Tumor DNA, Colorectal Neoplasms
Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

Study Overview
=================
Brief Summary
-----------------
This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.

Detailed Description
-----------------
Subjects will randomly enter into one of two groups,the period of treatment is 8 weeks.

Official Title
-----------------
Double-blind,Double-simulation,Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Iloperidone
* Drug: Risperidone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: men and women aged 18 to 65 years with schizophrenia; PANSS total score of at least 70 at screening and baseline; at least 2 more than 4 points in 7 of PANSS-P; informed consent. Exclusion Criteria: allergy with iloperidone or risperidone; psychotic symptoms failing to improve after sufficient exposure to 2 antipsychotic treatment; any other primary Axis 1 psychiatric diagnosis; a history of alcohol or drug dependence in recent 1 year; at imminent risk of harm to self or others; systolic blood pressure≤90mmHg。

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: oral iloperidone<br>2 12mg/day for 2 weeks,12 24mg/day for 6 weeks. | Drug: Iloperidone<br> <br> |
| Active Comparator: oral risperidone<br>1 3mg/day for 2 weeks,3 6mg/day for 6 weeks. | Drug: Risperidone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the score of Positive and Negative syndrome scale to evaluation the severity of schizophrenia |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the score of clinical global impressions to evaluation the severity of illness |  | 8 weeks | 
| the score of clinical global impressions to evaluation the improvement of illness |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Iloperidone, Risperidone, PANSS